Kirby McInerney LLP Announces Investigation Against Geron Corporation (GERN) on Behalf of Investors

Globe Newswire 27-Feb-2025 8:00 PM

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN). The investigation concerns whether Geron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[LEARN MORE ABOUT THE INVESTIGATION]

On February 26, 2025, Geron announced its financial results for the fourth year and full year 2024. During a related earnings call, Geron's executives said that the Company has "observed flat revenue trends over the last few months" for its recently approved blood disorder drug, Rytelo. On this news, the price of Geron shares declined by $0.76 per share, or approximately 32%, from $2.37 per share on February 25, 2025, to close at $1.61 on February 26, 2025.

If you purchased or otherwise acquired Geron securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out the form below to discuss your rights or interests with respect to these matters without any cost to you.

[CONTACT US]

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com